General Information of Drug (ID: DMCXN80)

Drug Name
Tozorakimab Drug Info
Indication
Disease Entry ICD 11 Status REF
Acute respiratory failure CB41.0 Phase 3 [1]
Chronic obstructive pulmonary disease CA22 Phase 3 [2]
Cross-matching ID
TTD Drug ID
DMCXN80

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting Interleukin-33 (IL33)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SAR440340 DMKYXSS Chronic obstructive pulmonary disease CA22 Phase 3 [4]
Itepekimab DMR8NDD Chronic obstructive pulmonary disease CA22 Phase 3 [4]
MEDI3506 DMDI7SA Chronic obstructive pulmonary disease CA22 Phase 3 [2]
AMG 282 DM92YWD Asthma CA23 Phase 1 [5]
PF-07264660 DM0GI2H Atopic dermatitis EA80 Phase 1 [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-33 (IL33) TT5MD4P IL33_HUMAN Inhibitor [3]

References

1 ClinicalTrials.gov (NCT05624450) A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen. U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT05742802) A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants With Chronic Obstructive Pulmonary Disease (COPD) With a History of Exacerbations. U.S.National Institutes of Health.
3 ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jul 31;21(1):691.
4 Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. N Engl J Med. 2021 Oct 28;385(18):1656-1668.
5 Clinical pipeline report, company report or official report of Amgen.
6 Clinical pipeline report, company report or official report of Pfizer